Hansa Medical AB (publ) Company Review & Valuation

HNSBF
OTC Markets
Latest Price
9.25USD

About Hansa Medical AB (publ)

Hansa Medical AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for transplantation and autoimmune diseases.

The company's lead drug candidate is Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), a proprietary antibody-degrading enzyme for kidney transplant patients, as well as for other solid organ transplants and acute autoimmune indications.

Its preclinical stage product candidates include Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy.

The company also has licensing agreement with Axis-Shield Diagnostics Ltd.

to develop Heparin Binding Protein (HBP)-assay, a novel diagnostic method that predicts severe sepsis in patients with infectious disease symptoms.

Hansa Medical AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.

Industry
HQ Location
Lund, Sweden

Stock Price

Price data not available for Hansa Medical AB (publ).

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl